



KETAMINE & RELATED COMPOUNDS

INTERNATIONAL HYBRID CONFERENCE 2022

Conference Program Day 1

Monday, 4th April

12.15 Registration

13.00 Welcome and Introduction

Speaker: Rupert McShane (University of Oxford, UK)

13.10 Glutamatergic modulators for treatment-resistant depression (TRD) and next generation antidepressants

Speaker: Carlos Zarate (National Institute of Mental Health, USA)

13.50 Mechanism for rapid and prolonged antidepressant action

Speaker: Lisa Monteggia (Vanderbilt University, USA)

14.30 KARE RCT of ketamine for alcohol use disorder: secondary and qualitative analyses

Speaker: Celia Morgan & Merve Mollaahmetoglu (University of Exeter, UK)

15.00 Tea

15.30 Cost-effectiveness of esketamine nasal spray compared to IV ketamine for Patients with TRD in the US utilizing clinical trial efficacy and real-world effectiveness estimates

Speaker: Madeline Brendle (The University of Utah, USA)

15.50 Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT)

Speaker: Pouya Movahed Rad (Lund University, Sweden)

16.20 Ketamine treatment for domain-based outcomes in persons with TRD

Speaker: Roger McIntyre (University of Toronto, Canada)

18.00 Reception, debate & brief tours of Duke Humfrey's library

This House believes that there is sufficient evidence for the wide prescription of ketamine for Treatment Resistant Depression

*Speakers For: Roger McIntyre (University of Toronto, Canada),
Gerard Sanacora (Yale University, USA)*

*Speakers Against: Joanna Moncrieff (University College London, UK),
Rupert McShane (University of Oxford, UK)*

Chair: Joan Marsh (Lancet Psychiatry, UK)



KETAMINE & RELATED COMPOUNDS

INTERNATIONAL HYBRID CONFERENCE 2022

Conference Program Day 2

Tuesday, 5th April - morning

- 09.00** Controlled release ketamine tablets for TRD – the Bedroc Study
Speaker: Paul Glue (University of Otago, NZ)
- 09.30** Oral esketamine for TRD: results of a randomized controlled trial and open-label treatment
Speaker: Sanne Smith-Apeldoorn (University of Groningen, The Netherlands)
- 09.45** Holding on or letting go? A qualitative study into patient experiences of control, context, and care in oral esketamine treatment
Speaker: Robert Schoevers (University of Groningen, The Netherlands)
- 10.00** CLE-100: an oral esketamine for daily at home administration
Speaker: Esther Hagai (Clexio Biosciences, Israel)
- 10.30** Coffee Break
- 11.00** Ketamine for pain and depression: from randomised clinical trials to real life evidence
Speaker: Gisèle Pickering (Clermont Université, France)
- 11.30** Ketamine modulates connectivity during autobiographical memory recall: a study in remitted depression
Speaker: Mitul Mehta (King's College London, UK)
- 11.45** Ketamine mechanisms and efficacy: a tale of two clinical trials with unexpected results
Speaker: Chadi Abdallah (Baylor College of Medicine, USA)
- 12.25** Lunch



KETAMINE & RELATED COMPOUNDS

INTERNATIONAL HYBRID CONFERENCE 2022

Conference Program Day 2

Tuesday, 5th April - afternoon

- 13.15** Negative affective bias: how ketamine turns the glass from half empty to half full
Speaker: Emma Robinson (University of Bristol, UK)
- 13.45** Corticotrophin releasing factor primes antidepressant responses to ketamine and (2R,6R)-hydroxynorketamine
Speaker: Polymnia Georgiou (University of Maryland, USA)
- 14.15** Long-term safety and sustenance of response with esketamine nasal spray in patients with TRD: interim results of the ongoing SUSTAIN-3 study
Speaker: Dong-Jing Fu (Janssen Pharmaceuticals, USA)
- 14.45** A brief, fully automated neurocognitive training intervention extends the antidepressant effect of a single ketamine infusion
Speaker: Rebecca Price (University of Pittsburgh, USA)
- 15.15** Tea
- 15.45** Recreational ketamine use is associated with high risk for depression among adolescents but not consistently among adults: results from two US nationally representative surveys
Speaker: Kevin Yang (University of California San Diego, USA)
- 16.05** Kynurenine pathway and biomarkers of response
Speaker: Rodrigo Machado-Vieira (University of Texas, USA)
- 16.30** Progress towards a subcutaneous ketamine and psychedelic formulations for pairing with an automated, wearable delivery system for use in pain management and mental health indications.
Speakers: Jeff Becker (Bexson Biomedical, USA) and Jason Wallach (University of the Sciences, USA)
-
- 18.45** Pre-dinner drinks – Balliol College Master’s Lodgings
- 19.10** Anatomy of Melancholy – What can Robert Burton teach us today?
Speaker: Kathryn Murphy (University of Oxford) – Balliol Dining Hall
- 19.30** Conference Dinner – Balliol Dining Hall



KETAMINE & RELATED COMPOUNDS

INTERNATIONAL HYBRID CONFERENCE 2022

Conference Program Day 3

Wednesday, 6th April - morning

- 09.00** Eight-week, midazolam controlled, RCT of subcutaneous ketamine for treatment resistant depression
Speaker: Colleen Loo (University of New South Wales, Australia)
- 09.30** IV ketamine for the treatment of severe suicidal ideation: results from a French multicenter RCT (KETIS)
Speaker: Fabrice Jollant (University of Nîmes, France)
- 10.00** Rapid agitation control with ketamine in the emergency department: a blinded, randomized controlled trial.
Speaker: David Barbic (University of British Columbia, Canada)
- 10.30** Sequenced ketogenic diet and ketamine infusions for chronic anorexia: a pilot study
Speaker: Lori Calabrese (Innovative Psychiatry, USA)
- 11.00** Coffee Break
- 11.30** Dissociatives: NMDA receptor antagonist pharmacology and structure activity relationships
Speaker: Jason Wallach (University of the Sciences, USA)
- 12.00** A single, ascending dose study of PCN-101 (R-ketamine)
Speaker: Terence Kelly (Perception Neuroscience, USA)
- 12.30** Rapid antidepressant effects and MADRS symptom improvements with AXS-05, an oral NMDA receptor antagonist, in major depressive disorder (MDD): results from two randomized, double-blind, controlled trials
Speaker: Amanda Jones (Axsome Therapeutics, USA)
- 13.00** Lunch



KETAMINE & RELATED COMPOUNDS

INTERNATIONAL HYBRID CONFERENCE 2022

Conference Program Day 2

Wednesday, 6th April - afternoon

- 13.45** Ketamine to prevent postpartum depression after planned cesarean delivery under neuraxial anesthesia: a randomized feasibility pilot-study of intravenous and subcutaneous administration
Speaker: David Monks (Washington University in St. Louis, USA)
- 14.15** Osmind real-world ketamine analyses
Speakers: Tuuli Hiematies (Stanford University, USA) and Alison McInnes (Osmind, USA)
- 14.35** Do all types of depression respond similarly? Real-world data on complex patient subgroups
Speaker: Joshua Rosenblat (University of Toronto, Canada)
- 15.10** Tea
- 15.30** REL-1017 (esmethadone hydrochloride) a novel uncompetitive NMDAR antagonist with a preference for NR1-NR2D subtypes shows rapid, robust, and sustained antidepressant effects as adjunctive treatment for MDD
Speakers: Paolo Manfredi & Marco Pappagallo (Relmada Therapeutics, USA)
- 16.00** 13 lessons learned from two decades of ketamine research
Speaker: Gerard Sanacora, Yale University, USA
- 16.45** Closing remarks
Speaker: Rupert McShane, University of Oxford, UK
-